370 related articles for article (PubMed ID: 26908325)
21. Detection and identification of potential biomarkers of non-small cell lung cancer.
Yang Y; Zhao S; Fan Y; Zhao F; Liu Q; Hu W; Liu D; Fan K; Wang J; Wang J
Technol Cancer Res Treat; 2009 Dec; 8(6):455-66. PubMed ID: 19925029
[TBL] [Abstract][Full Text] [Related]
22. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
23. Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study.
O'Shea K; Cameron SJ; Lewis KE; Lu C; Mur LA
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2682-7. PubMed ID: 27423423
[TBL] [Abstract][Full Text] [Related]
24. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
25. ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Fan W; Yang H; Xue H; Sun Y; Zhang J
Int J Clin Exp Pathol; 2015; 8(5):5503-8. PubMed ID: 26191257
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
27. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer.
Wang RJ; Zheng YH; Wang P; Zhang JZ
Int J Clin Exp Pathol; 2015; 8(1):765-71. PubMed ID: 25755772
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
29. A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
Guo J; Wang X; Wang Y; Wang L; Hua S
Lung Cancer; 2019 Sep; 135():47-55. PubMed ID: 31447002
[TBL] [Abstract][Full Text] [Related]
30. CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer.
Du Q; Li E; Liu Y; Xie W; Huang C; Song J; Zhang W; Zheng Y; Wang H; Wang Q
Cancer Med; 2018 Feb; 7(2):325-335. PubMed ID: 29356357
[TBL] [Abstract][Full Text] [Related]
31. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
32. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
33. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
34. Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.
Liang Y; Ma T; Thakur A; Yu H; Gao L; Shi P; Li X; Ren H; Jia L; Zhang S; Li Z; Chen M
Glycobiology; 2015 Mar; 25(3):331-40. PubMed ID: 25347993
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.
Infante M; Allavena P; Garlanda C; Nebuloni M; Morenghi E; Rahal D; Roncalli M; Cavuto S; Pesce S; Monari M; Valaperta S; Montanelli A; Solomon D; Bottoni E; Errico V; Voulaz E; Bossi M; Chiesa G; Passera E; Mantovani A; Alloisio M
Int J Cancer; 2016 Feb; 138(4):983-91. PubMed ID: 26348770
[TBL] [Abstract][Full Text] [Related]
36. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
37. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma.
Ahn YH; Shin PM; Oh NR; Park GW; Kim H; Yoo JS
J Proteomics; 2012 Sep; 75(17):5507-15. PubMed ID: 22789673
[TBL] [Abstract][Full Text] [Related]
38. Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology.
Pan J; Chen HQ; Sun YH; Zhang JH; Luo XY
Lung; 2008; 186(4):255-261. PubMed ID: 18465169
[TBL] [Abstract][Full Text] [Related]
39. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
40. [OLC1 protein levels in plasma of patients with non-small cell lung cancer and its clinical application].
Yang L; Xiao T; Tan J; Chen S; Gao Y; Cheng S; Liu X; Sun K
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):362-5. PubMed ID: 25030592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
